News & Events
June 30, 2022
Diamyd Medical Joins International Consortium in Type 1 Diabetes
Diamyd Medical will be a full voting member of the Type 1 Diabetes Consortium (T1DC) led by the US nonprofit organization Critical Path Institute (C-Path). The T1DC brings together diverse stakeholders from industry, academia and patient organizations to develop solutions to accelerate drug development for Type 1 Diabetes, including biomarker endpoints and model-informed drug development tools, in close collaboration with regulatory agencies to enable easier and faster regulatory approval of new treatments.
June 29, 2022
C-Path and Replica Analytics Collaboration Aims to Accelerate Rare Disease Research
C-Path and Replica Analytics, an Aetion company, announced today a new partnership that involves leveraging synthetic data to further catalyze the generation of actionable solutions to accelerate drug development for rare diseases.
June 22, 2022
C-Path Receives DIA 2022 Americas Inspire Award for Outstanding Contribution to Health
C-Path is pleased to announce it has received the DIA 2022 Americas Inspire Award for Outstanding Contribution to Health. This prestigious honor is conferred upon an individual, group or organization that has made significant and innovative contributions to advancing global health.
June 9, 2022
C-Path Launches Unique Translational Therapeutics Accelerator with Support from Cottrell Foundation
C-Path today announced it has been awarded a grant from the Frederick Gardner Cottrell Foundation, a non-profit organization established by Research Corporation Technologies, Inc. (RCT) that provides financial support for scientific research and educational programs, to create the C-Path Translational Therapeutics Accelerator (TRxA). The accelerator is a unique, global effort focused on supporting academic scientists in defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients.
June 7, 2022
C-Path and MitoAction Announce Data Sharing Agreement to Support Treatment Development in Mitochondrial Disease
C-Path and MitoAction today announced a joint collaboration to incorporate patient data for rare mitochondrial disorders into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).